An international group of scientists analyzed the effects of 17 lifespan-extending interventions on gene activity in mice and found genetic biomarkers of longevity. The results of their study had been published in the journal Cell Metabolism.
These days, dozens of interventions are known that extend the lifespan of diverse living organisms starting from yeast to mammals. They include chemical compounds, genetic interventions, and diets. Some targets of those interventions have been found. However, there’s still no clear understanding of the systemic molecular mechanisms affecting lifespan extension.
A team of scientists from Skoltech, Moscow State University, and Harvard University determined to fill this hole and identify crucial molecular processes related to longevity. To take action, they appeared at the results of varied lifespan-extending interventions on the activity of genes in a mouse, a generally used model organism closely associated with humans.
The scientists recognized a group of genes, whose exercise was associated with longevity in response to various interventions, serving as biomarkers of lifespan extension.
“In our lab, we subjected mice of different sexes and ages to 8 longevity interventions and analyzed gene expression changes induced by these therapies. After aggregating our data with the datasets printed by other teams, we obtained the gene activity profiles of 17 interventions. Although normally the effects produced by individual remedies turned out to be fairly particular, a certain group of genes modified its expression in a similar method in response to different lifespan-extending interventions,” says the first writer of the research, Alexander Tyshkovskiy.
The scientists then utilized the found biomarkers to seek for different interventions with an identical effect on their activity and, therefore, a high potential for lifespan extension. In their work, the researchers recognized several such treatments, together with chronic hypoxia and chemical compounds, such as the antioxidant ascorbyl palmitate and the mTOR inhibitor, KU-0063794.